title: Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals.
abstract: Soluble heparin displaces the cytokine hepatocyte growth factor (HGF) from heparan sulphate proteoglycans on the cell surface and in the extracellular matrix into the circulation. We examined serum HGF elevation after heparin injections, and whether there is a difference between unfractionated heparin (UH) and low molecular weight heparin (LMWH) in their ability to increase serum HGF. 20 healthy individuals were randomized to a single injection of intravenous or subcutaneous UH or LMWH. There was a significant increase in HGF from pretreatment values. This HGF was bioactive. When these preparations were compared on the basis of their serum concentrations (anti-factor Xa activity or molar concentrations), the increase in HGF was greater in individuals receiving UH than LMWH. When UH or LMWH were administered over a 5 d period, the increase in HGF, as well as the difference between treatments to induce HGF, remained stable throughout the treatment. In five patients treated with continuous intravenous heparin infusion HGF was increased throughout the treatment period of 5-7 d. In summary, the rise in bioactive HGF after heparin treatment was stable during continued treatment. UH was more potent in inducing HGF increase than LMWH, both after a single injection and after several days of treatment.
authors.affiliation: Institute of Cancer Research and Molecular Biology, Norwegian University of Science and Technology, Trondheim.
authors.forename: C
authors.initials: C
authors.lastname: Seidel
authors.forename: H
authors.initials: H
authors.lastname: Hjorth-Hansen
authors.forename: B
authors.initials: B
authors.lastname: Bendz
authors.forename: M
authors.initials: M
authors.lastname: Borset
authors.forename: P M
authors.initials: PM
authors.lastname: Sandset
authors.forename: J B
authors.initials: JB
authors.lastname: Hansen
authors.forename: A
authors.initials: A
authors.lastname: Sundan
authors.forename: A
authors.initials: A
authors.lastname: Waage
mesh_terms: D000293:Adolescent; D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage / Q000494:pharmacology*; D017985:Dalteparin / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D065427:Factor Xa Inhibitors; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000494:pharmacology*; D017228:Hepatocyte Growth Factor / Q000378:metabolism*; D006801:Humans; D007271:Injections, Intradermal; D007275:Injections, Intravenous; D008297:Male; D020246:Venous Thrombosis / Q000097:blood
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D017228:Hepatocyte Growth Factor; D006493:Heparin; D017985:Dalteparin